share_log

研报掘金丨国泰君安：云南白药23年业绩符合预期，维持“增持”评级

Research Report Nuggets丨Guotai Junan: Yunnan Baiyao's 23-year performance is in line with expectations and maintains an “gain” rating

Gelonghui Finance ·  Apr 3 04:00

According to the Guotai Junan Research Report, Yunnan Baiyao (000538.SZ)'s 23-year performance was in line with expectations. The core variety of Baiyao drugs and health products continued to grow at a high rate. Although profit disturbances in 23Q4 were obvious, overall disruptive factors decreased significantly, and the dividend ratio continued to be high, demonstrating confidence in future development. Maintain the target price of 63.36 yuan and the “Overweight” rating. The 23-year dividend plan is a dividend of 20.77 yuan for every 10 shares, with a total dividend of 3.706 billion yuan, accounting for 90.53% of net profit attributable to mother. The dividend ratio has continued to exceed 90% in the past two years.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment